157 related articles for article (PubMed ID: 31619767)
1. Transcribed B lymphocyte genes and multiple sclerosis risk genes are underrepresented in Epstein-Barr Virus hypomethylated regions.
Ong LTC; Parnell GP; Afrasiabi A; Stewart GJ; Swaminathan S; Booth DR
Genes Immun; 2020 Feb; 21(2):91-99. PubMed ID: 31619767
[TBL] [Abstract][Full Text] [Related]
2. Gender and the Sex Hormone Estradiol Affect Multiple Sclerosis Risk Gene Expression in Epstein-Barr Virus-Infected B Cells.
Keane JT; Afrasiabi A; Schibeci SD; Fewings N; Parnell GP; Swaminathan S; Booth DR
Front Immunol; 2021; 12():732694. PubMed ID: 34566997
[TBL] [Abstract][Full Text] [Related]
3. Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility.
Afrasiabi A; Parnell GP; Fewings N; Schibeci SD; Basuki MA; Chandramohan R; Zhou Y; Taylor B; Brown DA; Swaminathan S; McKay FC; Stewart GJ; Booth DR
Genome Med; 2019 Apr; 11(1):26. PubMed ID: 31039804
[TBL] [Abstract][Full Text] [Related]
4. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
[TBL] [Abstract][Full Text] [Related]
5. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
6. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines.
Elliott J; Goodhew EB; Krug LT; Shakhnovsky N; Yoo L; Speck SH
J Virol; 2004 Dec; 78(24):14062-5. PubMed ID: 15564516
[TBL] [Abstract][Full Text] [Related]
7. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
9. Host genetic variants and gene expression patterns associated with Epstein-Barr virus copy number in lymphoblastoid cell lines.
Houldcroft CJ; Petrova V; Liu JZ; Frampton D; Anderson CA; Gall A; Kellam P
PLoS One; 2014; 9(10):e108384. PubMed ID: 25290448
[TBL] [Abstract][Full Text] [Related]
10. The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype.
Keane JT; Afrasiabi A; Schibeci SD; Swaminathan S; Parnell GP; Booth DR
EBioMedicine; 2021 Sep; 71():103572. PubMed ID: 34488019
[TBL] [Abstract][Full Text] [Related]
11. The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis.
Afrasiabi A; Parnell GP; Swaminathan S; Stewart GJ; Booth DR
Sci Rep; 2020 Jan; 10(1):193. PubMed ID: 31932685
[TBL] [Abstract][Full Text] [Related]
12. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
13. Identification of multiple sclerosis-related genes regulated by EBV-encoded microRNAs in B cells.
Rang X; Liu Y; Wang J; Wang Y; Xu C; Fu J
Mult Scler Relat Disord; 2022 Mar; 59():103563. PubMed ID: 35114606
[TBL] [Abstract][Full Text] [Related]
14. TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection.
Namba-Fukuyo H; Funata S; Matsusaka K; Fukuyo M; Rahmutulla B; Mano Y; Fukayama M; Aburatani H; Kaneda A
Oncotarget; 2016 Dec; 7(49):81512-81526. PubMed ID: 27829228
[TBL] [Abstract][Full Text] [Related]
15. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
[TBL] [Abstract][Full Text] [Related]
16. The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion.
Hernando H; Shannon-Lowe C; Islam AB; Al-Shahrour F; Rodríguez-Ubreva J; Rodríguez-Cortez VC; Javierre BM; Mangas C; Fernández AF; Parra M; Delecluse HJ; Esteller M; López-Granados E; Fraga MF; López-Bigas N; Ballestar E
Genome Biol; 2013 Jan; 14(1):R3. PubMed ID: 23320978
[TBL] [Abstract][Full Text] [Related]
17. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.
Forte E; Salinas RE; Chang C; Zhou T; Linnstaedt SD; Gottwein E; Jacobs C; Jima D; Li QJ; Dave SS; Luftig MA
J Virol; 2012 Jun; 86(12):6889-98. PubMed ID: 22496226
[TBL] [Abstract][Full Text] [Related]
18. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
19. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation.
Tierney RJ; Kirby HE; Nagra JK; Desmond J; Bell AI; Rickinson AB
J Virol; 2000 Nov; 74(22):10468-79. PubMed ID: 11044091
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
J Virol; 2018 May; 92(9):. PubMed ID: 29467311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
